| Code | Description | Claims | Beneficiaries | Total Paid |
|---|
| 99283 |
Emergency department visit for the evaluation and management, moderate severity |
17,812 |
14,143 |
$2.18M |
| 99284 |
Emergency department visit for the evaluation and management, high severity |
11,200 |
8,750 |
$1.87M |
| G0378 |
Hospital observation service, per hour |
3,898 |
2,553 |
$896K |
| 99285 |
Emergency department visit for the evaluation and management, high severity with immediate threat to life |
3,858 |
2,672 |
$643K |
| 96374 |
Therapeutic, prophylactic, or diagnostic injection; intravenous push, single or initial substance |
5,760 |
3,797 |
$406K |
| 96372 |
Therapeutic, prophylactic, or diagnostic injection; subcutaneous or intramuscular |
10,540 |
6,975 |
$331K |
| A0425 |
Ground mileage, per statute mile |
4,418 |
2,414 |
$308K |
| 96365 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; initial, up to 1 hour |
4,387 |
2,457 |
$301K |
| 71045 |
Radiologic examination, chest; single view |
8,766 |
6,392 |
$289K |
| 97110 |
Therapeutic procedure, each 15 minutes; therapeutic exercises to develop strength and endurance, flexibility and range of motion |
13,019 |
2,706 |
$249K |
| 74177 |
Computed tomography, abdomen and pelvis; with contrast material |
1,286 |
1,040 |
$198K |
| 92507 |
Treatment of speech, language, voice, communication, and/or auditory processing disorder |
4,298 |
814 |
$191K |
| 93005 |
Electrocardiogram, routine ECG with at least 12 leads; tracing only, without interpretation and report |
9,343 |
6,597 |
$160K |
| 71046 |
Radiologic examination, chest; 2 views |
4,229 |
3,410 |
$159K |
| 70450 |
Computed tomography, head or brain; without contrast material |
3,348 |
2,591 |
$143K |
| 80307 |
Drug test(s), presumptive, any number of drug classes; immunoassay |
3,493 |
2,669 |
$142K |
| 99281 |
Emergency department visit for the evaluation and management, self-limited or minor |
3,165 |
1,856 |
$130K |
| 80053 |
Comprehensive metabolic panel |
19,776 |
14,047 |
$123K |
| 85025 |
Blood count; complete (CBC), automated, and automated differential WBC count |
24,234 |
16,197 |
$109K |
| 99282 |
Emergency department visit for the evaluation and management, low to moderate severity |
1,366 |
1,068 |
$96K |
| 96375 |
Therapeutic injection; each additional sequential IV push |
4,363 |
2,638 |
$92K |
| A0427 |
Ambulance service, advanced life support, emergency transport, level 1 (als 1 - emergency) |
2,679 |
2,064 |
$90K |
| 86900 |
|
1,506 |
1,227 |
$84K |
| 74176 |
Computed tomography, abdomen and pelvis; without contrast material |
702 |
591 |
$78K |
| 87428 |
|
1,581 |
1,269 |
$73K |
| 36415 |
Collection of venous blood by venipuncture |
30,043 |
19,724 |
$65K |
| 93306 |
Echocardiography, transthoracic, real-time with image documentation, with and without Doppler, complete |
384 |
322 |
$64K |
| 87804 |
Infectious agent antigen detection by immunoassay; Influenza, each type |
2,538 |
2,215 |
$63K |
| 87426 |
Infectious agent antigen detection, SARS-CoV-2 (COVID-19) |
2,268 |
1,827 |
$62K |
| 74018 |
|
1,474 |
1,187 |
$59K |
| 97161 |
|
1,646 |
1,334 |
$56K |
| 84484 |
|
7,645 |
4,270 |
$53K |
| 87491 |
Infectious agent detection by nucleic acid; Chlamydia trachomatis, amplified probe |
1,767 |
1,533 |
$47K |
| 87591 |
Infectious agent detection by nucleic acid; Neisseria gonorrhoeae, amplified probe |
1,757 |
1,524 |
$47K |
| 99291 |
Critical care, evaluation and management of the critically ill patient, first 30-74 minutes |
202 |
168 |
$47K |
| C9803 |
Hospital outpatient clinic visit specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
3,036 |
2,561 |
$46K |
| G0481 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 8-14 drug class(es), including metabolite(s) if performed |
523 |
422 |
$45K |
| 86850 |
|
1,447 |
1,185 |
$38K |
| 97530 |
Therapeutic activities, direct patient contact, each 15 minutes |
2,047 |
416 |
$37K |
| 83880 |
|
2,134 |
1,490 |
$37K |
| 96361 |
Intravenous infusion, hydration; each additional hour |
1,092 |
623 |
$33K |
| 80061 |
Lipid panel |
4,453 |
3,639 |
$33K |
| 82553 |
|
4,682 |
2,910 |
$32K |
| U0002 |
2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc |
869 |
802 |
$32K |
| 87430 |
|
2,350 |
2,063 |
$29K |
| 84443 |
Thyroid stimulating hormone (TSH) |
3,074 |
2,480 |
$29K |
| 87088 |
|
4,757 |
3,832 |
$27K |
| 86901 |
|
1,265 |
1,059 |
$23K |
| 82550 |
|
5,027 |
3,166 |
$22K |
| 80048 |
Basic metabolic panel (calcium, ionized) |
4,844 |
3,477 |
$22K |
| 81001 |
|
11,850 |
8,900 |
$22K |
| 94640 |
Pressurized or nonpressurized inhalation treatment for acute airway obstruction |
276 |
107 |
$21K |
| 96360 |
Intravenous infusion, hydration; initial, 31 minutes to 1 hour |
302 |
202 |
$19K |
| 87633 |
Infectious agent detection by nucleic acid, respiratory virus, 12-25 targets |
78 |
61 |
$19K |
| 83036 |
Hemoglobin; glycosylated (A1C) |
3,374 |
2,738 |
$19K |
| 96366 |
Intravenous infusion, for therapy, prophylaxis, or diagnosis; each additional hour |
593 |
177 |
$19K |
| 59025 |
Fetal non-stress test |
180 |
88 |
$18K |
| 73562 |
|
555 |
375 |
$18K |
| M0243 |
Intravenous infusion or subcutaneous injection, casirivimab and imdevimab includes infusion or injection, and post administration monitoring |
95 |
88 |
$18K |
| 72125 |
Computed tomography, cervical spine; without contrast material |
382 |
320 |
$17K |
| A0428 |
Ambulance service, basic life support, non-emergency transport, (bls) |
831 |
481 |
$17K |
| 87186 |
|
2,538 |
1,899 |
$15K |
| 87077 |
|
2,412 |
1,906 |
$15K |
| 87081 |
|
2,507 |
2,235 |
$14K |
| 73630 |
|
372 |
296 |
$13K |
| 82803 |
|
741 |
573 |
$11K |
| 81025 |
|
1,833 |
1,495 |
$10K |
| 83690 |
|
2,255 |
1,754 |
$10K |
| 82306 |
Vitamin D; 25 hydroxy, includes fraction(s), if performed |
607 |
474 |
$10K |
| 83605 |
|
1,673 |
1,183 |
$9K |
| 59050 |
|
263 |
159 |
$8K |
| 73610 |
|
193 |
161 |
$8K |
| 87086 |
Culture, bacterial; quantitative colony count, urine |
1,550 |
1,222 |
$8K |
| 96367 |
|
297 |
157 |
$8K |
| 84439 |
|
1,521 |
1,207 |
$7K |
| 87340 |
|
889 |
800 |
$7K |
| 87807 |
|
531 |
476 |
$6K |
| 85610 |
|
2,987 |
2,118 |
$6K |
| 82150 |
|
1,205 |
1,034 |
$6K |
| 85730 |
|
1,759 |
1,381 |
$6K |
| 73030 |
|
183 |
127 |
$6K |
| 86592 |
|
1,636 |
1,430 |
$5K |
| 86317 |
|
394 |
357 |
$5K |
| 85379 |
|
669 |
578 |
$5K |
| 84703 |
|
858 |
683 |
$4K |
| 82607 |
|
625 |
475 |
$4K |
| 94799 |
|
135 |
108 |
$4K |
| 87653 |
|
145 |
134 |
$4K |
| 86703 |
|
323 |
294 |
$4K |
| 87389 |
Infectious agent antigen detection by immunoassay technique, HIV-1 antigen with HIV-1 and HIV-2 antibodies |
277 |
204 |
$4K |
| 83735 |
|
1,434 |
881 |
$4K |
| 87070 |
|
703 |
518 |
$4K |
| 85018 |
|
2,130 |
1,819 |
$4K |
| 87040 |
|
651 |
454 |
$3K |
| 85014 |
|
2,015 |
1,726 |
$3K |
| J7040 |
Infusion, normal saline solution, sterile (500 ml = 1 unit) |
3,214 |
2,197 |
$3K |
| 97597 |
|
56 |
24 |
$3K |
| 0202U |
Oncology (prostate), multianalyte, gene expression profiling |
900 |
761 |
$3K |
| 73130 |
|
69 |
49 |
$2K |
| 76700 |
Ultrasound, abdominal, real time with image documentation; complete |
40 |
36 |
$2K |
| 83540 |
|
556 |
457 |
$2K |
| 82947 |
|
784 |
713 |
$2K |
| 84702 |
|
209 |
152 |
$2K |
| 87801 |
Infectious agent detection by nucleic acid; amplified probe, multiple organisms |
41 |
37 |
$2K |
| P9016 |
Red blood cells, leukocytes reduced, each unit |
18 |
12 |
$2K |
| 84466 |
|
197 |
171 |
$2K |
| 82077 |
|
278 |
192 |
$2K |
| 72110 |
|
33 |
25 |
$2K |
| 82728 |
|
171 |
142 |
$1K |
| 73502 |
|
35 |
29 |
$1K |
| 83655 |
|
128 |
116 |
$1K |
| 86677 |
|
107 |
96 |
$1K |
| 83550 |
|
195 |
150 |
$1K |
| J7050 |
Infusion, normal saline solution, 250 cc |
3,952 |
1,953 |
$953.57 |
| 81015 |
|
1,321 |
879 |
$895.12 |
| 90471 |
Immunization administration (includes percutaneous, intradermal, subcutaneous, or intramuscular injections), 1 vaccine |
29 |
28 |
$818.53 |
| 76856 |
Ultrasound, pelvic (nonobstetric), real time with image documentation; complete |
16 |
12 |
$629.28 |
| 77067 |
Screening mammography, bilateral, including computer-aided detection |
15 |
12 |
$548.77 |
| J0696 |
Injection, ceftriaxone sodium, per 250 mg |
4,549 |
3,045 |
$539.03 |
| 99238 |
Hospital discharge day management, 30 minutes or less |
17 |
17 |
$537.57 |
| 82570 |
|
222 |
160 |
$506.38 |
| 97140 |
Manual therapy techniques, each 15 minutes (e.g., mobilization/manipulation, manual lymphatic drainage) |
40 |
13 |
$503.92 |
| 82746 |
|
54 |
44 |
$474.81 |
| 82948 |
|
444 |
177 |
$437.86 |
| 94760 |
|
1,753 |
698 |
$361.30 |
| 80076 |
|
55 |
52 |
$347.04 |
| 86140 |
|
78 |
63 |
$268.22 |
| 85027 |
|
85 |
51 |
$221.16 |
| J1885 |
Injection, ketorolac tromethamine, per 15 mg |
4,701 |
3,289 |
$204.92 |
| 82043 |
|
82 |
58 |
$176.83 |
| G0480 |
Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including, but not limited to gc/ms (any type, single or tandem) and lc/ms (any type, single or tandem and excluding immunoassays (e.g., ia, eia, elisa, emit, fpia) and enzymatic methods (e.g., alcohol dehydrogenase)), (2) stable isotope or other universally recognized internal standards in all samples (e.g., to control for matrix effects, interferences and variations in signal strength), and (3) method or drug-specific calibration and matrix-matched quality control material (e.g., to control for instrument variations and mass spectral drift); qualitative or quantitative, all sources, includes specimen validity testing, per day; 1-7 drug class(es), including metabolite(s) if performed |
14 |
12 |
$175.16 |
| 86762 |
|
12 |
12 |
$155.40 |
| 85660 |
|
31 |
28 |
$145.28 |
| J2405 |
Injection, ondansetron hydrochloride, per 1 mg |
3,319 |
2,268 |
$121.22 |
| 84550 |
|
30 |
24 |
$118.50 |
| 85651 |
|
47 |
37 |
$110.46 |
| 84100 |
|
49 |
31 |
$93.94 |
| 84156 |
|
38 |
27 |
$84.93 |
| 36000 |
|
1,349 |
1,160 |
$73.39 |
| 82248 |
|
13 |
13 |
$72.73 |
| J1100 |
Injection, dexamethasone sodium phosphate, 1 mg |
1,395 |
1,006 |
$71.24 |
| G0433 |
Infectious agent antibody detection by enzyme-linked immunosorbent assay (elisa) technique, hiv-1 and/or hiv-2, screening |
694 |
635 |
$54.85 |
| G0103 |
Prostate cancer screening; prostate specific antigen test (psa) |
28 |
15 |
$52.14 |
| 82950 |
|
13 |
12 |
$50.73 |
| 85007 |
|
57 |
32 |
$34.20 |
| J2930 |
Injection, methylprednisolone sodium succinate, up to 125 mg |
64 |
52 |
$31.62 |
| G0283 |
Electrical stimulation (unattended), to one or more areas for indication(s) other than wound care, as part of a therapy plan of care |
660 |
175 |
$27.60 |
| J2001 |
Injection, lidocaine hcl for intravenous infusion, 10 mg |
2,348 |
1,952 |
$24.80 |
| J7030 |
Infusion, normal saline solution , 1000 cc |
599 |
315 |
$7.92 |
| Q9967 |
Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml |
492 |
311 |
$4.33 |
| J7120 |
Ringers lactate infusion, up to 1000 cc |
1,639 |
856 |
$0.78 |
| 96376 |
|
496 |
141 |
$0.15 |
| J0131 |
Injection, acetaminophen, not otherwise specified,10 mg |
375 |
183 |
$0.00 |
| J3490 |
Unclassified drugs |
1,928 |
963 |
$0.00 |
| J7613 |
Albuterol, inhalation solution, fda-approved final product, non-compounded, administered through dme, unit dose, 1 mg |
61 |
41 |
$0.00 |
| Q0162 |
Ondansetron 1 mg, oral, fda approved prescription anti-emetic, for use as a complete therapeutic substitute for an iv anti-emetic at the time of chemotherapy treatment, not to exceed a 48 hour dosage regimen |
206 |
136 |
$0.00 |
| J3010 |
Injection, fentanyl citrate, 0.1 mg |
47 |
40 |
$0.00 |
| J2250 |
Injection, midazolam hydrochloride, per 1 mg |
15 |
12 |
$0.00 |
| 99292 |
|
36 |
27 |
$0.00 |
| J1030 |
Injection, methylprednisolone acetate, 40 mg |
18 |
14 |
$0.00 |
| G0379 |
Direct admission of patient for hospital observation care |
14 |
12 |
$0.00 |
| J2704 |
Injection, propofol, 10 mg |
105 |
92 |
$0.00 |
| 80320 |
|
16 |
14 |
$0.00 |
| 77063 |
Screening digital breast tomosynthesis, bilateral |
15 |
12 |
$0.00 |
| J7620 |
Albuterol, up to 2.5 mg and ipratropium bromide, up to 0.5 mg, fda-approved final product, non-compounded, administered through dme |
25 |
12 |
$0.00 |
| 84145 |
|
854 |
606 |
$0.00 |
| J2550 |
Injection, promethazine hcl, up to 50 mg |
215 |
129 |
$0.00 |
| A6402 |
Gauze, non-impregnated, sterile, pad size 16 sq. in. or less, without adhesive border, each dressing |
1,135 |
475 |
$0.00 |
| J2270 |
Injection, morphine sulfate, up to 10 mg |
284 |
158 |
$0.00 |
| J1650 |
Injection, enoxaparin sodium, 10 mg |
974 |
482 |
$0.00 |
| G8978 |
Mobility: walking & moving around functional limitation, current status, at therapy episode outset and at reporting intervals |
58 |
55 |
$0.00 |
| G2023 |
Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source |
224 |
189 |
$0.00 |
| Q0244 |
Injection, casirivimab and imdevimab, 1200 mg |
81 |
74 |
$0.00 |
| 90715 |
|
14 |
13 |
$0.00 |
| G8979 |
Mobility: walking & moving around functional limitation, projected goal status, at therapy episode outset, at reporting intervals, and at discharge or to end reporting |
98 |
88 |
$0.00 |
| J3301 |
Injection, triamcinolone acetonide, not otherwise specified, 10 mg |
18 |
13 |
$0.00 |